Emmes CEO on AI in clinical research

Go back to Newsroom

Emmes CEO on AI in clinical research

Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research.

Go back to Newsroom

Patient-Caregiver Discrepancy Score: Multisite Evaluation of a Novel Pediatric Outcome Measure

Go back to Resources

Patient-Caregiver Discrepancy Score: Multisite Evaluation of a Novel Pediatric Outcome Measure

Authors:

Volume:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination

Go back to Resources

Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination

Authors:

Volume:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Differences in benefits of office based opioid treatment: Secondary analyses across sub-groups in the PROUD randomized controlled implementation trial

Go back to Resources

Differences in benefits of office based opioid treatment: Secondary analyses across sub-groups in the PROUD randomized controlled implementation trial

Authors:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Essex Management Appoints David Loose as Chief Executive Officer Appointment Reflects Commitment to Continuing Essex’s Strategic Vision ROCKVILLE, MD

Go back to Newsroom

Essex Management Appoints David Loose as Chief Executive Officer Appointment Reflects Commitment to Continuing Essex’s Strategic Vision ROCKVILLE, MD

Essex Management Appoints David Loose as Chief Executive Officer
[December 10, 2024] – Essex Management, an Emmes Group company and a leader in biomedical informatics and health information technology, is pleased to announce the appointment of David Loose as Chief Executive Officer (CEO), effective immediately. David succeeds Kevin Hurley, who has served as CEO since February 2019 and will transition to the role of Executive Advisor.

Go back to Newsroom

Mesoblast and BMT CTN to initiate pivotal trial of Ryoncil®

Go back to Newsroom

Mesoblast and BMT CTN to initiate pivotal trial of Ryoncil®

MESOBLAST AND BMT CTN TO INITIATE PIVOTAL TRIAL OF RYONCIL® AS PART OF FIRST-LINE REGIMEN IN ADULTS WITH SEVERE ACUTE GVHD REFRACTORY TO STEROIDS

Download Go back to Newsroom

Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccine

Go back to Resources

Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccine

Authors:

Volume:

Issue:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Implementation outcomes included in NIDA Clinical Trials Network (CTN) studies: A systematic review of studies conducted over 20 years

Go back to Resources

Implementation outcomes included in NIDA Clinical Trials Network (CTN) studies: A systematic review of studies conducted over 20 years

Authors:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate

Go back to Resources

Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate

Authors:

Volume:

Pagination:

Issue:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Safety and tolerability of RPESC-RPE transplantation in patients with dry age-related macular degeneration: Low-dose clinical outcomes

Go back to Resources

Safety and tolerability of RPESC-RPE transplantation in patients with dry age-related macular degeneration: Low-dose clinical outcomes

Authors:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Subscribe to